How Skyrizi Targets Psoriasis
Skyrizi (risankizumab) treats moderate to severe plaque psoriasis by blocking interleukin-23 (IL-23), a protein that drives inflammation in the skin. Psoriasis occurs when the immune system overproduces IL-23 and IL-17, leading to rapid skin cell growth and scaly plaques. Skyrizi binds specifically to the p19 subunit of IL-23, preventing it from activating T-cells and stopping the inflammatory cascade at its source.[1][2]
Patients typically receive two 150 mg subcutaneous injections at weeks 0 and 4, then every 12 weeks. This selective inhibition reduces plaque severity, with clinical trials showing 75-90% skin clearance (PASI 90) in many patients by week 16.[3]
Why IL-23 Blockade Works Better Than Older Treatments
Unlike broad immunosuppressants like methotrexate, which affect multiple immune pathways and raise infection risks, Skyrizi targets only IL-23. This precision minimizes side effects while achieving faster, deeper responses. Studies confirm it outperforms TNF inhibitors (e.g., Humira) in head-to-head trials for psoriasis clearance.[2][4]
Common Side Effects Patients Experience
Upper respiratory infections occur in about 15% of users, along with headaches and fatigue. Serious risks include infections like tuberculosis (screening required) and rare hypersensitivity reactions. Long-term data show sustained efficacy with low discontinuation rates.[1][3]
How Skyrizi Compares to Other Biologics
| Drug | Target | Dosing Frequency | PASI 90 Rate (Week 16) |
|------|--------|-------------------|-------------------------|
| Skyrizi | IL-23 p19 | Every 12 weeks | 75-88%[3] |
| Tremfya (guselkumab) | IL-23 p19 | Every 8 weeks | 73-80%[4] |
| Cosentyx (secukinumab) | IL-17A | Every 4 weeks | 70-80%[4] |
| Taltz (ixekizumab) | IL-17A | Every 4 weeks | 80-82%[4] |
Skyrizi's less frequent dosing improves adherence. It also works for psoriatic arthritis, unlike some IL-17 inhibitors limited to skin symptoms.[2]
Who Qualifies and When Results Appear
Approved for adults with ≥10% body surface area affected who failed topical or oral therapies. Visible improvement starts by week 4; full effects peak at 16 weeks. Not for mild cases or active infections.[1]
Patent Status and Generic Timeline
Skyrizi's key composition-of-matter patent (U.S. Patent No. 8,119,600) expires in 2028, with formulation patents extending to 2033. No generics approved yet; biosimilar challenges expected post-2028.[5]
Sources
[1]: Skyrizi Prescribing Information (FDA)
[2]: Mechanism of Action - AbbVie
[3]: ULTIMMA-1/2 Trials (NEJM)
[4]: Head-to-Head Comparisons (JAMA Dermatology)
[5]: DrugPatentWatch.com - Risankizumab Patents